Page last updated: 2024-11-05

uridine diphosphate glucuronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uridine Diphosphate Glucuronic Acid: A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

UDP-alpha-D-glucuronic acid : A UDP-sugar having alpha-D-glucuronic acid as the sugar component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID17473
CHEMBL ID228057
CHEBI ID17200
MeSH IDM0022350

Synonyms (62)

Synonym
gtpl1784
uridine 5'-[3-(alpha-d-glucopyranuronosyl) dihydrogen diphosphate]
uridine-5'-diphosphate-glucuronic acid
udp-alpha-d-glucuronic acid
CHEBI:17200 ,
alpha-d-glucopyranuronic acid, 1-p'-ester with uridine 5'-(trihydrogen diphosphate)
UGA ,
uridinediphosphoglucuronic acid
uridine diphosphoglucuronic acid
udp glucuronic acid
uridine 5'-diphospho-glucuronic acid
udpglucuronate
uridine diphosphate glucuronic acid
udp-alpha-d-glucuronate
udp-d-glucuronate
udp-glucuronic acid
C00167
UDP-GLUCURONATE ,
DB03041
uridine 5'-diphosphoglucuronic acid
udpga
CHEMBL228057 ,
BMSE000292
(2s,3s,4s,5r,6r)-6-[[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
uridine 5''-[3-(alpha-d-glucopyranuronosyl) dihydrogen diphosphate]
bdbm50209665
uridine-5'-diphosphoglucuronic acid
04szc4mefq ,
unii-04szc4mefq
udp-.alpha.-d-glucuronic acid
.alpha.-d-glucopyranuronic acid, 1->p'-ester with uridine 5'-(trihydrogen diphosphate)
uridine 5'-diphospho-.alpha.-d-glucuronic acid
uridine 5'-diphosphate alpha-d-glucopyranuronic acid
glucopyranuronic acid 1-ester with uridine 5'-pyrophosphate
uridine 5'-[3-(d-glucopyranosyloxyuronic acid) dihydrogen diphosphate]
uridine pyrophosphoglucuronic acid
uridine pyrophosphoglucuronate
alpha-delta-glucopyranuronic acid 1-p'-ester with uridine 5'-(trihydrogen diphosphate)
a-d-glucopyranuronic acid 1->5'-ester with uridine 5'-(trihydrogen pyrophosphate)
uridine 5'-diphospho-a-d-glucuronic acid
a-d-glucopyranuronic acid ester with uridine 5'-pyrophosphate
alpha-d-glucopyranuronic acid 1-p'-ester with uridine 5'-(trihydrogen diphosphate)
uridine 5'-diphospho-alpha-delta-glucuronic acid
udp-delta-glucuronate
uridine diphosphate-glucuronate
uridine diphospho-d-glucuronic acid
uridine diphospho-delta-glucuronic acid
alpha-delta-glucopyranuronic acid 1->5'-ester with uridine 5'-(trihydrogen pyrophosphate)
alpha-delta-glucopyranuronic acid ester with uridine 5'-pyrophosphate
udp-alpha-delta-glucuronate
uridine 5'-diphosphoglucuronate
uridine diphospho-d-glucuronate
uridine 5'-diphospho-a-d-glucuronate
udp-delta-glucuronic acid
uridine diphospho-delta-glucuronate
udp glucuronate
uridine 5'-diphospho-alpha-delta-glucuronate
(2s,3s,4s,5r,6r)-6-{[(s)-{[(r)-{[(2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(hydroxy)phosphoryl]oxy}(hydroxy)phosphoryl]oxy}-3,4,5-trihydroxytetrahydro-2h-pyran-2-carboxylic acid (non-preferred name
DTXSID00903961
udp-|a-d-glucuronic acid
Q277638
HDYANYHVCAPMJV-LXQIFKJMSA-N

Research Excerpts

Overview

Uridine diphosphate glucuronic acid (UDPGA) is an essential substrate in the glucuronidation of exogenous and endogenous lipophilic compounds. Its synthesis depends on glucose and energy in the body.

ExcerptReferenceRelevance
"Uridine diphosphate glucuronic acid (UDPGA) is an essential substrate in the glucuronidation of exogenous and endogenous lipophilic compounds via the liver glucuronic acid pathway, and its synthesis depends on glucose and energy in the body. "( Continuous exposure to bisphenol S increases the accumulation of endogenous metabolic toxicants by obstructing the glucuronic acid pathway.
Li, J; Li, Z; Ru, S; Wang, W; Yang, Y, 2023
)
2.35

Toxicity

ExcerptReferenceRelevance
"Age-related changes in glucuronidation may potentially lead to a decrease in excretion of reactive compounds, resulting in enhanced toxic effects."( The effect of age on the glucuronidation and toxicity of 4,4'-thiobis(6-t-butyl-m-cresol).
Birnbaum, LS; Borghoff, SJ; Stefanski, SA, 1988
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Its pharmacokinetic properties have been investigated using both in vitro and in vivo models, and the resulting data extrapolated to patients."( Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Kestell, P; Paxton, JW; Zhou, S, 2002
)
0.31
" The in vivo clearance of tanshinone IIA was acquired from a pharmacokinetic study in rat."( The prediction of the hepatic clearance of tanshinone IIA in rat liver subcellular fractions: accuracy improvement.
Khlentzos, A; Li, J; Li, P; Liu, X; Roberts, MS; Wang, GJ; Zhang, Q, 2008
)
0.35
" We now report full pharmacokinetic (PK) data, correlations of PK with clinical outcomes, and final response and progression-free survival (PFS)."( Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D, 2009
)
0.35
" Thus, the pharmacokinetic changes of LQ and its 2 glucuronides, M1 and M2, in a rat model of diabetes mellitus induced by streptozotocin (DMIS rats) were evaluated."( Liquiritigenin pharmacokinetics in a rat model of diabetes mellitus induced by streptozotocin: greater formation of glucuronides in the liver, especially M2, due to increased hepatic uridine 5'-diphosphoglucuronic acid level.
Baek, SR; Kang, HE; Lee, JW; Lee, MG; Sohn, SI, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" If patients receive morphine and these drugs simultaneously, the drug-drug interaction may change the levels of morphine and these glucuronides, resulting in altered analgesic efficacy and the risk of side effects."( Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine.
Hara, Y; Miyamoto, K; Nakajima, M; Yokoi, T, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Possible mechanisms contributing to the incomplete oral bioavailability of dasatinib in animals were investigated."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008
)
0.35
" Absorption and first-pass metabolism were evaluated as possible reasons for the incomplete oral bioavailability using various in vitro and in vivo models like Caco-2 cells, P-glycoprotein (P-gp) knockout mice, and intra-portal dosing in rats."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008
)
0.35
" Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008
)
0.35
" The incomplete oral bioavailability may be due to both incomplete absorption and high first-pass metabolism."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008
)
0.35
"The interplay between phase II enzymes and efflux transporters leads to extensive metabolism and low bioavailability for flavonoids."( UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.
Hu, M; Jiang, W; Wu, B; Xu, B; Yu, R, 2012
)
0.38
"To explain the low bioavailability of sibiricaxanthone F (SF) following oral administration and to predict its possible metabolites in vivo, the in vitro biotransformation of SF and its metabolic stability in intestinal bacteria (BI) were studied."( Characterization of the metabolism of sibiricaxanthone F and its aglycone in vitro by high performance liquid chromatography coupled with Q-trap mass spectrometry.
Jiang, Y; Song, Y; Tu, P; Yang, X, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The metabolites described above were all detected in bile collected from a rat dosed with verlukast."( In vitro and in vivo biotransformations of the potent leukotriene D4 antagonist verlukast in the rat.
Nicoll-Griffith, D; Rasori, R; Trimble, L; Williams, H; Yergey, J; Zamboni, R,
)
0.13
" The time course of the decline in PAPS values after 600 mg acetaminophen/kg showed that PAPS concentrations reached a nadir 1 hr after dosing (40% of control values)."( Acetaminophen decreases adenosine 3'-phosphate 5'-phosphosulfate and uridine diphosphoglucuronic acid in rat liver.
Hazelton, GA; Hjelle, JJ; Klaassen, CD,
)
0.13
" Absorption and first-pass metabolism were evaluated as possible reasons for the incomplete oral bioavailability using various in vitro and in vivo models like Caco-2 cells, P-glycoprotein (P-gp) knockout mice, and intra-portal dosing in rats."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
UDP-D-glucuronic acidA UDP-sugar having D-glucopyranuronic acid as the sugar component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (57)

PathwayProteinsCompounds
Nucleotide Sugars Metabolism817
Androgen and Estrogen Metabolism1230
Porphyrin Metabolism1636
17-beta Hydroxysteroid Dehydrogenase III Deficiency1230
Ibuprofen Action Pathway5076
Celecoxib Action Pathway3573
Starch and Sucrose Metabolism1626
Acute Intermittent Porphyria1636
Porphyria Variegata (PV)1636
Congenital Erythropoietic Porphyria (CEP) or Gunther Disease1636
Hereditary Coproporphyria (HCP)1636
Irinotecan Action Pathway2411
Etoposide Action Pathway2014
Tamoxifen Action Pathway1027
Phenytoin (Antiarrhythmic) Action Pathway6923
Codeine Action Pathway3420
Morphine Action Pathway4716
Nicotine Action Pathway3832
Galactosemia II (GALK)817
Galactosemia III817
Glycogen Synthetase Deficiency1626
Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis1626
Glycogenosis, Type IV. Amylopectinosis, Anderson Disease1626
Glycogenosis, Type VI. Hers Disease1626
Mucopolysaccharidosis VII. Sly Syndrome1626
Sucrase-Isomaltase Deficiency1626
Aromatase Deficiency1230
Ibuprofen Metabolism Pathway2414
Irinotecan Metabolism Pathway2411
Etoposide Metabolism Pathway2014
Tamoxifen Metabolism Pathway1027
Codeine Metabolism Pathway411
Morphine Metabolism Pathway176
Nicotine Metabolism Pathway923
Valproic Acid Metabolism Pathway1132
Tramadol Metabolism Pathway717
Acetaminophen Metabolism Pathway3016
Nevirapine Metabolism Pathway821
Celecoxib Metabolism Pathway811
Sorafenib Metabolism Pathway1612
Artemether Metabolism Pathway410
Mycophenolic Acid Metabolism Pathway1618
Amino Sugar and Nucleotide Sugar Metabolism III2340
Colanic Acid Building Blocks Biosynthesis1723
Polymyxin Resistance418
Androstenedione Metabolism1823
Estrone Metabolism1622
Ascorbate Biosynthesis414
Proteoglycan biosynthesis011
Metabolic pathways of fibroblasts1718
galactose degradation III017
Relationship between glutathione and NADPH036
Ascorbate and aldarate metabolism07
Colanic acid building blocks biosynthesis014
Starch and cellulose biosynthesis09
Biochemical pathways: part I0466
Valproic acid pathway022
Glucuronidation014

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 14Homo sapiens (human)EC50 (µMol)0.37000.16000.37650.6700AID286300; AID450300
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayP2Y purinoceptor 14Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled UDP receptor activityP2Y purinoceptor 14Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneP2Y purinoceptor 14Homo sapiens (human)
membraneP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID450303Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells up to 10 uM2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID286300Agonist activity at human P2Y14 expressed in COS7 cells assessed as stimulation of PLC-mediated [3H]inositol hydrolysis2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.
AID450300Agonist activity at human P2Y14 receptor expressed in human COS7 cells2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID1346395Rat P2Y14 receptor (P2Y receptors)2001Genomics, Dec, Volume: 78, Issue:3
Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs.
AID1346390Human P2Y14 receptor (P2Y receptors)2009The Journal of pharmacology and experimental therapeutics, Jul, Volume: 330, Issue:1
Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems.
AID1346389Mouse P2Y14 receptor (P2Y receptors)2001Genomics, Dec, Volume: 78, Issue:3
Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (469)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990179 (38.17)18.7374
1990's91 (19.40)18.2507
2000's115 (24.52)29.6817
2010's66 (14.07)24.3611
2020's18 (3.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.41 (24.57)
Research Supply Index6.22 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.40%)5.53%
Reviews18 (3.59%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other482 (96.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]